Literature DB >> 3172118

Coexistence of CREST syndrome and primary biliary cirrhosis. Serological studies of two cases.

M Hirakata1, M Akizuki, K Miyachi, H Matsushima, T Okano, M Homma.   

Abstract

Two patients with characteristic features of CREST syndrome and primary biliary cirrhosis are reported. Sera of both patients contained autoantibodies to centromere and mitochondrial antigens. Immunodiffusion analysis identified the specificities of precipitating antibodies to mitochondria of the first case as anti-M-A and M-C, and of the second case as anti-M-A and M-B antibodies. Simultaneous occurrence of 2 marker antibodies in an individual patient indicates that the 2 patients reported here have CREST syndrome and primary biliary cirrhosis, both of which are considered as a distinct clinical entity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3172118

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Shared autoimmunity: the time has come.

Authors:  Donato Alarcón-Segovia
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

3.  A case of limited cutaneous systemic sclerosis developing anti-mitochondria antibody positive primary biliary cirrhosis after acute myocardial infarction.

Authors:  Kiyomitsu Miyachi; Raleigh Hankins; Minoru Ihara; Akira Miyamoto; Tetsuroh Okano; Miwako Iwai; Katsuhiko Mikoshiba; Marvin J Fritzler
Journal:  Clin Rheumatol       Date:  2006-11-25       Impact factor: 2.980

4.  Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties.

Authors:  Ewa Wielosz; Maria Majdan; Iwona Zychowska; Radosław Jeleniewicz
Journal:  Rheumatol Int       Date:  2008-03-05       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.